Challenges in Management of Autoimmune Hepatitis With Concurrent Graves Thyrotoxicosis

Ngan Nguyen, MD1, Yala Kirthi Reddy, MD1, Nidhi Jain, MD2, Vanisha Patel, BS3, Deirdre James, MD2, Bobbak Sistani, MD1, and Helmut Steinberg, MD2

1Department of Internal Medicine, University of Tennessee Health Science Center, Memphis, TN
2Department of Endocrinology, University of Tennessee Health Science Center, Memphis, TN
3University of Tennessee Health Science Center, Memphis, TN

ABSTRACT

The management of concurrent Graves thyrotoxicosis and autoimmune hepatitis (AIH) can be challenging. We present a 37-year-old woman with a recent diagnosis of Graves disease and acute liver injury. Laboratory workup was concerning for AIH. Liver biopsy showed plasma cell infiltration and interface hepatitis consistent with AIH, and treatment with methylprednisolone was initiated. Azathioprine was started after thiopurine methyltransferase testing, and prednisone was tapered down. Thionamide use was contraindicated, so clinical euthyroidism was achieved with the use of cholestyramine and glucocorticoids. Our case highlights the complexities of management when patients are affected by 2 concurrent illnesses.

INTRODUCTION

Autoimmune hepatitis (AIH) is an inflammatory liver disease caused by a T-cell-mediated reaction to liver antigens, leading to a necroinflammatory and fibrotic process in the liver.1 Plasma cell-rich mononuclear infiltrate mainly involving portal and periportal regions along with interface hepatitis is the characteristic feature of AIH but usually nonspecific.2 Standard treatment includes combination steroid and azathioprine initiation unless there is some contraindication to azathioprine with the ultimate goal for maintenance to gradually withdraw steroid (Class I, Level A recommendation).3 In the United States, thyrotoxicosis caused by Graves disease is the most common one. Thionamides are the first-line medications for Graves disease along with nonselective β-blockers for the treatment of thyrotoxicosis.4 Guidelines recommend extreme caution regarding initiating antithyroid drug therapy when liver enzyme levels are elevated greater than 5-fold or above the upper limit of normal.5 Few case reports exist about the association with hyperthyroidism and AIH.6,7

CASE REPORT

A 37-year-old African American woman with a history of recently diagnosed Graves hyperthyroidism 1-month before presented to the emergency department with complaints of fatigue, diarrhea, severe jaundice, worsening heat intolerance, and palpitations for 4 days and weight loss of 30 lbs over 6 months. The patient was not on any antithyroid medications before coming to the hospital. She had a history of increased alcohol intake (3 beers daily) but was sober for the past 2 months. Screening for drugs, alcohol, acetaminophen, and recent hepatotoxic medication use were all negative.

The patient had scleral icterus, dry mucous membranes, diffusely enlarged but nontender thyroid, and brisk reflexes. The baseline liver function is detailed in Table 1. Acute hepatic damage was suspected. The thyroid function test showed elevated free triiodothyronine (T3) at 5.86 pg/mL and free thyroxine (T4) at 5.06 pg/mL with a suppressed thyroid stimulating hormone level at less than 0.005 μU/mL and elevated thyrotropin receptor antibody (Table 1). Her international normalized ratio at admission was...
was 1.8; however, the patient was not encephalopathic. Ultrasound of the neck showed diffuse enlargement of both sides of the thyroid gland with hypervascularity. A full sepsis workup was negative for any infection except for *Clostridium difficile*. Abdominal and pelvic computed tomography showed no evidence of biliary dilatation but some nonspecific periportal edema and lymphadenopathy in the porta hepatis. Her hepatitis profile was negative, and serum quantitative immunoglobulins (IgG) showed markedly elevated IgG1 level (1910 mg/dL).

**Table 1. Laboratory data on admission and discharge**

| Test                                      | Normal values     | At admission | At discharge |
|--------------------------------------------|-------------------|--------------|--------------|
| **Thyroid function test**                  |                   |              |              |
| Free T4                                    | 0.76–1.46 ng/dL   | 5.06         | 2.78         |
| Free T3                                    | 2.18–3.98 pg/mL   | 5.86         | 1.95         |
| TSH                                        | 0.358–0.374 μU/mL | <0.005       | Not performed|
| TRAb                                       | 0–1.75 U/L        | 7.47         | Not performed|
| TSI                                         | <140              | Not performed| 139          |
| **Liver function test**                    |                   |              |              |
| Alkaline phosphatase                       | 45–117 U/L        | 314          | 231          |
| AST                                        | 15–37 U/L         | 2,828        | 284          |
| ALT                                        | 13–56 U/L         | 2,725        | 672          |
| Total bilirubin                            | 0.2–1 mg/dL       | 9.4          | 11.3         |
| Direct bilirubin                           | <0.2 mg/dL        | 1.3          | 9            |
| **Hematology**                             |                   |              |              |
| WBC                                        | 4.5–11.0 × 10^3/L | 7.7          | 10.3         |
| Hgb                                        | 6.6–20 g/dL       | 13.7         | 11.1         |
| Hematocrit                                 | 34.6%–43.8%       | 40.9         | 32.5         |
| Platelet                                   | 150–400 × 10^9/L  | 177          | 153          |
| **Immunology workup**                      |                   |              |              |
| IgG1                                       | 382–929 mg/dL     | 1,910        | Not performed|
| IgG2                                       | 241–700 mg/dL     | 371          | Not performed|
| IgG3                                       | 22–178 mg/dL      | 120          | Not performed|
| IgG4                                       | 4–86 mg/dL        | 39           | Not performed|
| **Microbiology workup**                    |                   |              |              |
| C. Diff toxin B by PCR                     | N/A               | Positive     | Not performed|
| Hepatitis A IgM AB                         | N/A               | Negative     | Not performed|
| Hepatitis B Surf Antigen                   | N/A               | Negative     | Not performed|
| Hepatitis B Core IgG AB                    | N/A               | Negative     | Not performed|
| Hepatitis B Core IgM AB                    | N/A               | Negative     | Not performed|
| Hepatitis B Core antibody total            | N/A               | Nonreactive  | Not performed|
| Hepatitis C antibody                       | N/A               | Negative     | Not performed|
| HIV 1, 2 antibody                          | N/A               | Nonreactive  | Not performed|
| CMV IgG antibody                           | 0–7.9 EU/mL       | 145.7        | Not performed|
| CMV DNA, quantity by PCR                   | N/A               | Undetected   | Not performed|
| HSV-1 IgG antibody                         | <0.9 index        | 54.3         | Not performed|
| HSV-2 IgG antibody                         | <0.9 index        | >23          | Not performed|
| HSV-1 DNA, quantity by PCR                 | <100 copies/mL    | <100         | Not performed|
| HSV-2 DNA, quantity by PCR                 | <100 copies/mL    | <100         | Not performed|

ALT, alanine aminotransferase; AST, aspartate aminotransferase; CMV, cytomegalovirus; HCV, hepatitis C virus; HSV, herpes simplex virus; IgG, immunoglobulin G; IgM, immunoglobulin M; PCR, polymerase chain reaction; TRAb, thyrotropin receptor antibody; TSH, thyroid stimulating hormone; TSI, thyroid stimulating immunoglobulin; WBC, white blood cell.
Autoimmune and infectious workup for acute liver failure were obtained before initiating steroid therapy (Table 1). Considering the history of autoimmune thyroid disease and elevated serum IgG, the suspicion for AIH was heightened. Although her cytomegalovirus (CMV) and herpes simplex virus (HSV) IgG antibodies were high, the CMV and HSV 1 and 2 DNA were undetectable, suggesting previous CMV and HSV exposure. The antimitochondrial antibody, antismooth muscle antibodies, and antinuclear antibody tests were all negative. Liver biopsy performed 4 days after admission revealed plasma cell infiltration and interface hepatitis consistent with a diagnosis of AIH (Figure 1).

Our patient had hypergammaglobulinemia with IgG1 level of 1910 mg/dL. Her international AIH group score was 6, which suggested the probable diagnosis of AIH. On the other hand, her revised original AIH score was 21, signifying “definite AIH.”

High-dose intravenous methylprednisolone at 40 mg every 8 hours and cholestyramine at 4 mg twice a day was initiated, and β-blockade with propranolol at 40 mg once resumed. Owing to a contraindication to thionamide use, a trial of cholestyramine was attempted to control thyrotoxicosis. The patient responded well to intravenous steroids and oral cholestyramine. After the initiation of glucocorticoids, her transaminases and free T3 and T4 levels trended down (Figure 2). The results of the Quantiferon Gold test and hepatitis B virus core laboratory test and thiopurine methyltransferase status were negative. Azathioprine was added, and glucocorticoid was tapered.

The patient was discharged home with oral prednisone at 60 mg once daily with a tapering plan, azathioprine 100 mg once daily, cholestyramine 4 mg daily, and nadolol 40 mg daily. Six months after discharge, the patient remained clinically euthyroid with a low maintenance dose of oral prednisone 15 mg daily and propranolol 40 mg once daily. Her thyroid stimulating hormone level 9 months after discharge was normalized to 0.3 μU/mL. The patient opted out of Graves definitive treatment, such as thyroidectomy or radioactive iodine ablation. Her liver function test has returned to normal with the use of azathioprine.

**DISCUSSION**

Graves disease can be associated with other autoimmune diseases such as type 1 diabetes, pernicious anemia, rheumatoid arthritis, and systemic lupus; however, its association with AIH is rarely reported. Although the actual etiologies that trigger AIH remain unclear, there has been a hypothesis that viral exposures could play a role in the induction of an autoimmune process. Our patient had elevated CMV and HSV antibody with undetectable viral DNA, indicating previous exposure to both CMV and HSV. Our patient had chronic hepatitis at baseline (aspartate aminotransferase 150, alanine aminotransferase 100) 2 months before, which could be from alcohol use vs...
AIH. As her Graves thyrotoxicosis began to manifest, the liver function began to worsen and eventually progressed to acute liver injury. There was rapid improvement in liver and thyroid function after initiation of steroid therapy.

In individuals with Graves hyperthyroidism concomitant with acute liver injury, treatment is challenging because thionamides can worsen liver injury.13 The 2 definitive treatments are surgery and radioactive iodine ablation. Urgent thyroidectomy is risky in individuals who are acutely thyrotoxic with acute liver damage. Radioiodine ablation is a safer option, but the overall inhibitory effect is often temporary because of a return of high thyroid hormone concentration from escape phenomenon.14 As a result, cholestyramine, nadolol, and glucocorticoid were used as an adjuvant therapy. Glucocorticoid suppresses the immune response process in both Graves disease and AIH and inhibits peripheral T4 to T3 conversion. Cholestyramine, a bile-salt sequestrant, binds to thyroid hormones in the intestine and increases its excretion. Cholestyramine is used as an adjunctive therapy in treating thyrotoxicosis but has no role in treating AIH. Rapid improvement of both liver and thyroid function was achieved after glucocorticoid and cholestyramine initiation. Our case highlights a rare manifestation of acute liver damage from AIH in the setting of Graves disease and outlines how a clinician can approach a similar scenario.

DISCLOSURES

Author contributions: All authors contributed equally to this manuscript. YK Reddy is the article guarantor.

Financial disclosure: None to report.

Informed consent was obtained for this case report.

Received June 29, 2019; Accepted September 30, 2019

REFERENCES

1. Krawitt EL. Autoimmune hepatitis. N Engl J Med. 2006;354(1):54–66.
2. Oo YH, Hubscher SG, Adams DH. Autoimmune hepatitis: New paradigms in the pathogenesis, diagnosis, and management. Hepatol Int. 2010;4(2):475–93.
3. Sanchez-Urdapil L, Czaja AJ, van Hoek B, Krom RAF, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology. 1992;15(2):215–21.
4. Guan HX. What’s new in the 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Zhonghua nei ke za zhi. 2017;56(10):785–8. [Chinese].
5. Singer PA, Cooper DS, Levy EG, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. JAMA. 1995;273(10):808–12.
6. Rana S, Ahmed Z, Salgia R, Bhan A. Successful management of patients with coexistent Graves’ disease and autoimmune hepatitis. Careus. 2019;11(5):e4647.
7. Papadakis GE, Lamine F, Chitiou H, et al. Rapid remission of Graves’ hyperthyroidism without thionamides under immunosuppressive treatment for concomitant autoimmune hepatitis. Thyroid. 2018;28(2):276–8.
8. Balitzer D, Shafizadeh N, Peters MG, Ferreri LD, Alshak N, Kakar S. Autoimmune hepatitis: Review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria. Mod Pathol. 2017;30(5):773–83.
9. Alvarez F, Berg PA, Bianchi FB, et al. International autoimmune hepatitis group report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31(5):929–38.
10. Boelaert K, Newby PR, Simmonds MJ, et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med. 2010;123(2):183.
11. Skoog SM, Rivard RE, Batts KP, Smith CI. Autoimmune hepatitis preceded by acute hepatitis A infection. Am J Gastroenterol. 2002;97(6):1568–9.
12. Vento S, Caielli F, Renzini C, Concia E. Autoimmune hepatitis type 2 induced by HCV and persisting after viral clearance. Lancet. 1997;350(9087):1298–9.
13. Otsuka F, Nob YH, Chino T, et al. Hepatotoxicity and cutaneous reactions after antithyroid drug administration. Clin Endocrinol (Oxf). 2012;77(2):310–5.
14. Eng PH, Cordona GR, Fang SL, et al. Escape from the acute Wolff-Chaikoff effect is associated with a decrease in thyroid sodium/iodide symporter messenger ribonucleic acid and protein. Endocrinology. 1999;140(8):3404–10.

Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.